Member Info for WengerOut

Has someone just gone all in and bought in 200,000 & 250,000 chunks this morning, very strange day in the office for AMC shares!

Seen some larger buys the last couple of days, are people finally looking at AMC as an undervalued investment? We are worth less than £10 million with billions in the ground, surely a re-rate coming soon.

Thanks for your balanced postings Red Lee, always appreciate them, still holding in here and hopefully shareholders will get some value here by the end of the year.

Oh look, this idiot only joined LSE yesterday and claims he is selling something he hasn’t bought, so transparent, go away silly troll.

Ridiculous amount of shares in issue now, this takeover looks a desperate act to appease shareholders which wouldn’t have happened if it wasn’t for our recent drilling disaster, good luck to those remaining, might be back sometime in 2021 if things change but can’t see anything positive here for a while.

Time to call him again

Amur Minerals Corp www.amurminerals.com
Robin Young, CEO Tel: +7 (4212) 755615

And straight into auction, long long way for this to go.

Might take a little longer but still plenty to play for, my other stock Amur Minerals is finally moving, £30 billion of metal in the ground and a ridiculous market cap of £13 million, the biggest anomaly on AIM.

Please tell me someone didn’t just ask what the HRZ was??!

True value will win out, just need to keep patient, we are in the home straight now, I doubt AMC will be around this time next year, what price we will be taken out I don't know but it will be multiples of today's price, how many is the question, just keep adding at this ridiculous low level.

We are currently valued around the same as a square headed Man Utd defender, crazy!
Many multiples to go up yet from here.

Ignore that, just seen it posted below!

Can someone post what it says as I can’t download a PDF on my iPhone, thanks in advance.

97.65p more to to go until I sell :-)

....and I'm off to The Globe for lunch, should really make an effort to go to one of these meetings there, especially as its on my doorstep, LOL.

Then we go and ask the questions, he could have done the 10% raise AFTER this event so he is either brave or stupid, I think we are in for a pleasant surprise, see you all there!

Continuing the rise back to the 40's, about time, so much to look forward to here.

Extremely low market cap for the potential here, added more this morning, wasn’t expected to get in under 25p

https: // www . businessweekly .co .uk/news/local-sharewatch/avacta-raising-%C2%A392m-fund-fresh-global-spurt

25 October, 2019 - 18:44 By Tony Quested

Avacta raising £9.2m to fund fresh global spurt

Cambridge UK life science business Avacta Group plc is raising up to £9 million through a share placing and subscription exercise on AIM. The company is developing Affimer® biotherapeutics and research reagents.

FinnCap is acting as nominated adviser and joint broker alongside WG Partners and Turner Pope who will also be acting as joint brokers in connection with the placing. Neither the placing nor subscription is to be underwritten.

The money is designed to allow Avacta to deliver the next key value inflection points in its global expansion strategy. These are chiefly:-
•The phase 1 clinical trial of AVA6000 pro-doxorubicin;
•Continuing to advance Affirmer immunotherapy pipeline with partners
•Delivering further commercial progress for therapeutics and diagnostics.

In July the company obtained advance assurance from HMRC that a subscription for new ordinary shares was capable of qualifying for EIS tax reliefs.

The issue price is at a discount of approximately 11.8 per cent to the closing price of the ordinary shares on AIM to October 17 (17p per share).
Avacta also reveals a good year to July 31; it now has cash balances of £6.5m – up from £5.2m year-on-year.

The revenues of £4.1m were greater than expectation (£2.8m FY18) due to recognition of an up-front milestone payment of $2.5m from LG Chem Life Sciences.

The operating loss of £11.2m – up from £10.4m last time – was due to significant investment in research and development, which increased to £5.9m (£3.8m). The increased R & D investment led to a reported loss of £9.7m (£8.8m).

CEO Alastair Smith said: “I am very pleased to see the strong growth in Affimer® reagents revenue and order intake over the reporting period.

“This has been driven by the growing reputation of the Affimer technology particularly in the diagnostics and pharmaceutical sectors; two markets where the company will be focusing our resources in the reagents business going forwards.

“We have numerous evaluation projects ongoing with large diagnostics partners, each of which could lead to a lucrative licence deal. To reduce the time taken to reach the point of signing licence deals, we are close to completing the first two in-house Affimer diagnostic assays, as set out last year. Building a profitable Affimer reagents business remains a high priority for the group.”

Good volume today, nice to see blue, the fall was well overdone, placement out the way, onwards and upwards!